...
首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
【24h】

Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.

机译:合成(+)-顺式-N-(4-异硫氰酸根合苄基)-N-去甲咪唑啉,N-苄基去甲恶唑啉的异硫氰酸酯衍生物,作为σ(1)受体的酰基化剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

(+)-cis-N-(4-Isothiocyanatobenzyl)-N-normetazocine (BNIT) (+)-(4) was designed and synthesized as a derivative of the potent and selective sigma(1) receptor ligand (+)-cis-N-benzyl-N-normetazocine for irreversibly blocking sigma(1) binding sites. Pretreatment of guinea pig brain membranes with BNIT (0.1, 1, and 5 microM) caused a concentration-dependent loss of binding of the selective sigma(1) ligand [(3)H]-(+)-pentazocine. Binding experiments with [(3)H]-1,3-di(2-tolyl)guanidine ([(3)H]-DTG), a ligand of sigma(1) and sigma(2) receptors, showed that pretreatment with BNIT blocked only the sigma(1) component of [(3)H]-DTG binding.
机译:设计和合成(+)-顺-N-(4-异硫氰酸根合苄基)-N-去甲恶唑啉(BNIT)(+)-(4)作为有效和选择性sigma(1)受体配体(+)-顺式的衍生物-N-苄基-N-去甲佐辛不可逆地阻止sigma(1)结合位点。用BNIT(0.1、1和5 microM)预处理豚鼠脑膜会导致选择性sigma(1)配体[(3)H]-(+)-喷他佐辛的浓度依赖性损失。与[(3)H] -1,3-di(2-tolyl)胍([(3)H] -DTG),sigma(1)和sigma(2)受体的配体的结合实验表明,用BNIT仅阻止[(3)H] -DTG绑定的sigma(1)组件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号